Jefferies Global Healthcare Conference in London - CVRX INC
Good afternoon, everybody, and welcome to the Jeffries Global Healthcare Conference of 2026. It is my pleasure to introduce you to Kevin Hikes and John Landry, the CEO and CFO of CVRx. Okay, good afternoon. Thank you. It's my pleasure of being able to speak to you today. I know it's been a long week. It is Thursday, for those of you that are still checking, but we're pleased to be here. CVRx, these are our forward looking statements further information is obviously on our website but CVRX has developed the world's first autonomic neuromodulation therapy for the treatment of heart failure we operate in a 10.5 billion dollar TAM with a well defined patient population and a very differentiated technology and our goal is to drive barostim to become the standard of care for the treatement of heart failure I will acknowledge our stock has been under significant pressure recently there's a clear dislocation between the value of this enterprise and the value of the opportunity as we see it, and some headwinds in our market that I'll talk about. But I want to be clear, the fundamentals of the market and the opportunity and the value proposition for clinicians and patients are fully intact. So I hope I can share a little more of that with you today. Heart failure is a significant condition. It affects 6.7 million Americans alone. It affects every facet of their life. It drives significant health care cost, including over a million hospital discharges, a million emergency room visits, 8 million physician office visits, and will drive upwards of $70 billion in expense in the U.S. alone by 2030, so a very significant chronic disease condition. It is characterized by a steady decline over the course of the disease, and when diagnosed, patients are initiated on what's called quad therapy, a mixture of four pharmacologic agents, which are considered guideline-directed treatment today for heart failure. A small number of them are considered for therapy called cardiac resynchronization therapy, or CRT. But for the most part, the patients are sent home. Ten years later, eight to ten years later. One percent of them, one percent of the patients, are evaluated for a cardiac transplant or for a left ventricular assist device. But in the intervening six to eight years, they are home suffering from significant quality-of-life issues and debilitating symptoms. And so this is a paradigm that's been in place for about 50 years. Patients are started on drugs. They're told that it's a horrible disease and that they should go home and just suffer, and that in 10 years or so they may be a candidate for transplant or LVAD. That represents 1% of patients who receive those therapies. So that's the paradigm that we're trying to change with CVRx. The quad therapy, these pharmacologic agents, it does, in fact, extend life by one to six years. However, only 1% of patients ever take all four of those drugs at a therapeutic level, and by the end of the first year, 40% of those patients discontinue at least one of those drugs. Additionally, while it may extend life one to six years, the drugs do nothing for quality of life or symptoms. This leaves patients suffering significant issues with quality of life, with the activities of daily living with mental health issues with pain and discomfort and when queried these patients in multiple surveys over and over again say they don't wish to live any longer they wish to live better and they would gladly give up years of longevity in exchange for an improvement in their symptoms so those are the patients we're trying to address that the patients in the middle of this eight to ten year journey they're often referred to by the heart failure community as the walking wounded or the forgotten middle. And those are patients whose paradigm needs to change in order to address this condition. Importantly, those patients in the purple window represent a 10 million dollar TAM on a prevalence basis. So this is a significant opportunity. We are one of very few medical devices in this field. We're on the front end of the introduction of devices to this very pharmacologically driven field. That's a challenge, but it's a tremendous opportunity both for our company and to help the patients and physicians who struggle with this disease. I'll give you a quick background on the therapy itself. So barostim improves heart failure symptoms by targeting the same neurohormonal pathway that the drugs address. So this is the fundamental understanding of heart failure as a disease. It's a neurohormal disorder, much like a metastasized heart disease. So the body's natural thermostat is a group of nerves called the baroreceptor. They're in your neck on either side on the top of your carotid artery. And with each heartbeat, the baroreceptor sends a signal to the brain describing the cardiovascular condition of the body. In the presence of heart failure, those signals are reduced progressively over time as the disease progresses. And the challenge is the heart interprets that reduced signal as a signal of crisis, and it activates the fight or flight response. Heart failure is effectively a fight or fight response on overdrive that never stops. So barostim restores that signaling from the carotid baroreceptor to the brain and dials down the fight-or-flight response, pulling back on the sympathetic tone, the body's accelerator, and restoring parasympathetic control to the heart, and in doing so, significantly reduces the symptoms associated with the disease. And again, this complements, it does not replace or compete with drug therapy, it complements them by turning down effectively the storm that the drugs are trying to shield your body's organs from. So it's very complementary and well understood by the physician community. Patients that are eligible for barostim are on these four drugs, or as many of them as they can tolerate and will take. They have a left ventricular ejection fraction less than 35%, and they have a blood marker called NT-PRO-BNP of 1,600 or less. That's a little bit esoteric, but it describes the stability of their heart failure at a given time. And they're in New York Heart Class 2 or 3. So they're in the middle of that heart disease journey that I described earlier. The system is implanted in a 60-minute procedure with a 97% freedom from complications. It's comprised of a pacemaker-like device and a small single silicone wire that extends from the chest to be placed on top of the carotid baroreceptor on the outside of the carotide artery. It is performed typically on an inpatient basis. It requires a very small incision in the neck and chest, and it's entirely extravascular, which is important. There are no leads or hardware in the vasculature or in the heart. Our pivotal trial, the BEAT-HF trial, demonstrated that barostim is an effective, predictable, and durable therapy to improve quality of life in heart failure patients. It represented a two-times clinically meaningful improvement in exercise capacity and quality of life. 68% of the patients improved their functional status, and it had a 94% responder rate, which is very significant for any medical therapy, drug or device included. Our go-to-market strategy has three key focal points. The first is improving the productivity of our sales team. The second is driving deep adoption in targeted centers, and the third is addressing the fundamental barriers to the adoption of this therapy that exists in the heart failure community. In terms of Salesforce productivity, we know that tenure and turnover are critical to our ability to execute on our commercial plan. Stability at both the territory manager level and the leadership level is critical, and I'm pleased to share that as of Q3, the turnover in our company has reached the lowest level in two years, and the tenure of our sales team has reached an all-time high. This is encouraging. It's been something we've been working on. We would expect on a long-term basis to have roughly average turnover rates for a business in our industry. But this is a positive signal indeed. We've been very deliberate about stabilizing this team through the many changes we've had to make in the course of our commercial transformation. Importantly, we installed a trusted veteran CBRX executive as our interim sales leader in August when we had to making a change. We have created new sales leadership roles and staffed them from within our team to deal with span of control issues and try to improve the time available to our sales leaders to onboard new sales reps and get them productive as quickly as possible, and we've been aggressive at implementing sales retention compensation plans to ensure that that turnover stays low. As we mentioned on our Q3 call, most of the turnover that we've experienced is focused in four of our nine sales regions, both at the territory manager level and the sales leadership level. When we look at performance across all nine of these regions, we see that in the five regions that have significant tenure and lower turnover, we're growing our business at 20-plus percent. And we're going to do that because those regions, given their tenure and experience, are executing our playbook effectively. That means using the right sales tools in the right conversations in the Right Centers. It means driving a deep referral focus in the community around our centers, and by doing those two things, they are reaching 45% more health care professionals than the newer colleagues with less tenure in the four struggling regions, and in doing so are identifying 24% more patient candidates. So we believe that our playbook, when executed, works and can, in fact, drive significant double-digit growth. So our focus is on getting those four struggling regents and the tenure of those newer employees improved with onboarding and training and coaching to deliver the same level of execution. The second element of our commercial strategy involves driving deep adoption in the right sorts of centers. And what that looks like starts with an aligned network of stakeholders. That includes referrers that surround the center, a prescriber that actually evaluates the patient and prescribes the therapy, and a surgeon that understands how to implant the device. And they're supported by not just a clinical champion, but often a financial champion or an administrative champion that understands the very attractive economic nature of this procedure to a hospital system. With that alignment, we can establish a unified workflow. That's sort of the recipe that helps identify a patient in the community who may be a candidate, directs them to a physician that can evaluate them and prescribe the therapy, and on to a surgeon who can effectively implant it. And when that workflow is appropriately and effectively implemented, we see very consistent and positive outcomes. And those positive outcomes drive the flywheel effect that we're trying to achieve. They drive consistent depth of adoption at the account level. That's what good looks like. While the heart failure specialists are important gatekeepers and often our first point of contact in these centers, Our most productive centers are characterized by deep referral networks, both within the four walls of the center itself, but also, and more importantly, in the community surrounding the centers. That's where many of our Class II and III patients are being treated today. And we know that our most productive center has six times more referrers than the early-stage centers. So, again, that's an objective of our sales team is driving the creation of these networks around the centers on our third quarter call we also discussed an emerging headwind in our market something we thought was transient but we now understand will likely be dealing with for some time and that relates to the chronic under staffing of heart failure specialists in the united states specifically and that that is a challenge that is caused by the small the relatively limited specialty there's only 1400 heart failure specialist in the in the United States that's a very small number of physicians for a disease state of this size. It's driven by a chronic under-filling of the fellowship role. So in this last year, only 43% of heart failure fellowships were filled. So we're making fewer and fewer new heart failure physicians each year, making this problem even worse. And what that means for our business is that there's almost a constant job-hopping effect between these heart failure specialists. There are so many open roles that every 18 months to 24 months, the good heart failure specialists are being plucked away to a new and different center. And what that, it doesn't necessarily mean we lose business permanently, but it often disrupts a center, shuts it down for a number of months, and it takes time to get a new program established where that champion goes for their next assignment. So it's not a loss of business, but it's certainly a confounding factor and causes disruption in our business. The program selling strategy I described is the strongest tool we have to mitigate this challenge. And that starts by building redundancy across that network and reducing our reliance on a specific physician. It continues with efforts to stabilize and align and make as healthy as possible the program itself so that it can survive some disruptions. And importantly, long term, and what we're starting to see, is it involves the creation of a referral pathway from the community directly to the surgeon. So these are experienced community referrers that the heart failure community says, I trust you, you understand what the right patients look like, I don't need to be involved anymore. So that's the best tool we have to reduce the reliance on the specific heart failure specialist and mitigate the impacts of this job-hopping dynamic that is clearly part of today's world. The third element of our go-to-market strategy involves reducing the systemic or global barriers to the adoption of the therapy that exists in our market, and there are three of them. And in our case, they're sort of motherhood and apple pie. These are right up the middle. It's awareness amongst the heart failure community in how a medical device might be used to treat this condition that's historically been treated with drugs. Number two, it's developing enough evidence that physicians of different levels of conservatism can understand what to expect, understand what patients might benefit, and can communicate that effectively with patients. And number three is patient access, which is a constant issue and obviously a barrier for any new therapy, whether it's in heart failure or elsewhere. So as it relates to awareness, we know that the most effective programs involve significant numbers of referrers, both in the center and in the community surrounding the center. So we're leveraging new AI-based tools to identify and target the most productive referreras that send heart failure patients regularly for other procedures into these heart failure centers. and we can target them specifically with messaging and medical education. We're increasing significantly our offering of medical education events and programming to try to meet that demand to really, again, build those networks that are so productive around the centers that are beginning to use barostem therapy. As it relates to evidence, the strategy we put in place 18 months ago is bearing fruit, and we're now seeing a significant increase and steady cadence of publications on barostim therapy. 19 publications to date, the most on record for any year, with 18 different lead authors. And this is part of a broader strategy that's really aimed at building around the original Phase III trial results, the BEAT-HF trial results which proved that it was safe, effective, and durable, and better examining a number of secondary clinical outcomes and trying to understand how does this affect hospitalization, how does it affect drug therapy. And in many cases, patients who receive our therapy are better able to tolerate these drugs because their blood pressure is more stable, looking at arrhythmia rates, looking at kidney function, other factors that are important to clinicians as they think about something that's this novel in treating this disease. We're also spending a lot of time trying to better describe and prove the mechanism of action, the systemic impact of this therapy on the condition and on the human body. And that relates to how the heart remodels, how the hemodynamics improve and change, the ejection fraction of the heart, and ultimately what we've now seen in multiple studies is the reduction in inflammatory biomarkers. Heart failure is a systemic inflammatory disease. It starts with the heart, but it's effectively metastasized. So these are important for different physicians with different hot buttons. These are important proof points that we need to convince them that, in fact, a medical device is an appropriate treatment for this disease. At the recent Heart Failure Society of America meeting last month, our largest meeting of the year, we had a record nine podium and poster presentations representing this therapy across a number of those dimensions I just described, the most important of which was a 425-patient two-year follow-up in the rebalance registry. Rebalance is the largest data set ever presented for the barostim therapy, and it demonstrated sustained and significant improvement in a number of clinical metrics, including, importantly, NYHA class and ejection fraction. So further supporting and buttressing the fundamentals of this therapy. We've talked in the past about how we're beginning to now, like many companies, in our position to leverage real-world evidence to support the therapy as well. We presented data last year from the Premier Healthcare Database, a U.S. database involving 1,300 hospitals and 3 to 4 million patients, where we showed in 306 barostem patients a remarkable 85% reduction in hospitalization before and after receiving this therapy with a p-value of 0.001 so important data for payers and clinicians alike real world evidence represents an important and developing field for companies like ours because it's of great value to payers clearly who are looking at the health economics data you can derive from these databases it's important to facilitating quick and efficient evidence generation it can be a development platform for fda pathways there's now a real-world evidence-based pathway that the FDA has announced in the last year that allows for the expansion of labeling claims based on data such as this. So it's an important area of investment for us, and we're excited about the opportunity to leverage it to its fullest. In May of this year, we launched the BenefitHF trial, which will be the largest therapeutic device trial in the history of heart failure. It'll involve 2,500 patients at 150 centers, and if successful, will triple our TAM to roughly $30 billion. We believe it'll take roughly four years to enroll the trial and another two years to follow the last patient. So this is a significant long-term investment that we're making, but it's a signal to the community that we believe in the therapy, we have confidence in the outcomes, and that we are putting our money where our mouth is. And the reactions from the heart failure community have been very positive, and the credibility that this brings to us from a scientific level and a commitment level has been a tailwind in our commercial business as well. So we're excited about the therapy. We're not going anywhere, and we believe that it can, in fact, fundamentally change the way this disease is treated. So on the third front, reimbursement and patient access, we are making great progress. In this last round of CMS data, we achieved for the first time 100% coverage from a Medicare fee-for-service population basis. So that's a significant step forward. On the Medicare Advantage side, our other major population, we now have two written coverage policies from Humana and Devoted Health, which is a significant step forward. We are in the portion of the battle with the payers in the United States that's a bit like a domino effect. And as you amass more and more written coverage polices, you gain more leverage over payers, and you can ultimately trigger a class effect where everyone will have to write a coverage policy on the therapy if their competitors are doing so. So we're in that battle now. On the third quarter call, we discussed a significant headwind that we've been dealing with now for three quarters that relates to our largest payer and our most predictable payer, and that involves a dramatic change in their behavior over the last three quarters that brought their approval rate from 83 plus percent down to 12 percent as of the end of Q3. This is a transient situation, but it's one that has significantly impacted our growth in the last year. We believe it can, in fact, be mitigated, and we're working to establish a written coverage policy like Humana and Devoted Health with this particular payer from two avenues. The first is at a strategic or policy level, leveraging their competitor's behavior, bringing it to their attention, and helping them understand the importance of writing a policy of their own so that they can compete effectively, bringing evidence to bear with each successive publication in real time, helping them understand the current state of clinical evidence development for the therapy, and ultimately securing an off-cycle review for the potential decision to write a policy. So not waiting until the train comes around a year later, but getting them to agree on an off-cycle basis to take a fresh look. From the bottoms-up level, tactically, we are fighting these payers patient by patient. And we have a team in-house that handles about 35% of our prior authorization requests and contests each and every denial from a payer all the way through to the ultimate end, which is an administrative law judge review. And by doing so, we create enough friction and enough cost for the payers, and ultimately, if they lose enough of these decisions to the administrative law judge, it can trigger a written policy. So, again, top-down and bottoms-up, both the objective of delivering another written policy, ideally from this very large payer, first and foremost. so while our rates have declined in q3 versus q2 from 60 percent down to 51 percent as a result of this headwind i described the overall rates are improving and we are making slow and steady progress with patient access we will be fighting this fight for years to come but we're pleased with what we're seeing and we're confident that we will ultimately be able to sufficiently secure access for patients who can benefit. So in closing, we believe we have an important therapy that can substantially impact patient quality of life and physician care for this critical disease. We are committed to doing so. We appreciate that this necessary commercial transformation has taken longer than we would have anticipated. The depth of changes that we had to make were deeper than we anticipated. And we certainly have some headwinds that we're dealing with. But we are resolute in progressing this therapy to standard of care. We believe that the fundamental opportunity and the value proposition is secure and that by pressing forward we can change the lives of patients and create significant value in doing so. Thank you for your time. Appreciate the chance to speak to you today. Thank you. Take a question if we have two minutes. Thank you. Have a good week. . . . . . . . . . . . . . . . . . . . . . . . . . .
- Company
- CVRX INC
- Keywords
- CVRX INC